| Market Cap | 3.39B | P/E | - | EPS this Y | 3.40% | Ern Qtrly Grth | -61.50% |
| Income | -471M | Forward P/E | 2.52 | EPS next Y | 15.20% | 50D Avg Chg | 13.00% |
| Sales | 9.2B | PEG | 0.67 | EPS past 5Y | -5.65% | 200D Avg Chg | 22.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | 2.60% | 52W High Chg | -9.00% |
| Recommedations | 3.00 | Quick Ratio | 0.62 | Shares Outstanding | 367.10M | 52W Low Chg | 88.00% |
| Insider Own | 11.28% | ROA | 4.16% | Shares Float | 275.87M | Beta | 0.75 |
| Inst Own | 78.99% | ROE | -2,304.55% | Shares Shorted/Prior | 19.83M/19.72M | Price | 9.33 |
| Gross Margin | 70.80% | Profit Margin | -5.12% | Avg. Volume | 3,585,993 | Target Price | 7.64 |
| Oper. Margin | 17.60% | Earnings Date | Oct 31 | Volume | 2,346,502 | Change | -1.48% |
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
| RBC Capital | Sector Perform | Aug 2, 24 |
| Piper Sandler | Underweight | Aug 2, 24 |
| Truist Securities | Hold | Jul 25, 24 |
| Raymond James | Market Perform | Jul 10, 24 |
| RBC Capital | Sector Perform | Apr 23, 24 |
| RBC Capital | Sector Perform | Apr 12, 24 |
| RBC Capital | Sector Perform | Apr 5, 24 |
| RBC Capital | Sector Perform | Feb 23, 24 |
| Jefferies | Buy | Sep 20, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Carson Seana | EVP, General Counsel EVP, General Counsel | Nov 03 | Sell | 7.61 | 43 | 327 | 384,836 | 11/06/23 |
| Carson Seana | EVP, General Counsel EVP, General Counsel | Feb 27 | Sell | 9.32 | 292 | 2,721 | 359,185 | 03/01/23 |
| Spurr Robert | U.S. President-Pharm.. U.S. President-Pharma Business | Apr 14 | Sell | 22.19 | 1,595 | 35,393 | 90,506 | 04/15/22 |
| Gordon Joseph F | Pres&Co-Head Bausch&.. Pres&Co-Head Bausch&Lomb/Int'l | Mar 08 | Sell | 21.76 | 3,889 | 84,625 | 93,139 | 03/10/22 |
| Gordon Joseph F | Pres&Co-Head Bausch&.. Pres&Co-Head Bausch&Lomb/Int'l | Feb 26 | Sell | 23.82 | 6,338 | 150,971 | 112,179 | 03/02/22 |
| Spurr Robert | U.S. President-Pharm.. U.S. President-Pharma Business | Jan 18 | Sell | 26.63 | 3,251 | 86,574 | 63,550 | 01/20/22 |
| Miller Steven D | Director Director | Nov 30 | Buy | 24.2 | 60,000 | 1,452,000 | 10,000 | 12/02/21 |
| Humphries William D. | President, Ortho-Der.. President, Ortho-Dermatologics | Dec 08 | Option | 14.38 | 114,055 | 1,640,111 | 349,090 | 12/08/20 |
| Humphries William D. | President, Ortho-Der.. President, Ortho-Dermatologics | Dec 08 | Sell | 19.87 | 114,055 | 2,266,273 | 235,035 | 12/08/20 |